Other
Refractory AML
0
Pipeline Programs↗
3
Active Trials↗
3
Companies Involved↗
Refractory AML is an early-stage landscape with 0 programs across 3 companies. The most active players are Chongqing Precision Biotech Co., Ltd, Actinium Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
16
clinical trials
Terminated5 · 31%
Completed5 · 31%
Unknown status3 · 19%
Recruiting2 · 13%
Not yet recruiting1 · 6%
Clinical Trials
Trial Activity
16 trials
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Recruiting·—·Phase 2·NCT06536959·67 enrolled
Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML
Completed·—·Phase 1·NCT02891278·6 enrolled
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
Terminated·—·Phase 1·NCT02109627·17 enrolled
Decitabine, Cytarabine, GCSF for Refractory AML/MDS
Terminated·—·Phase 2·NCT00740181·9 enrolled
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 3·NCT03384225·120 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)